Biocompatibility and osseointegration properties of a novel high strength and low modulus β- Ti10Mo6Zr4Sn3Nb alloy

Jiantao Liu, Kao Wang, Xingyuan Li, Xiwei Zhang, Xi Gong, Yihan Zhu, Zhiwei Ren, Bin Zhang, Jun ChengFrontiers in Bioengineering and Biotechnology 2023 · DOI

Abstract

Introduction: While Ti6Al4V is the current standard for orthopedic implants, it suffers from a high elastic modulus leading to stress shielding and contains potentially toxic elements. This study evaluates Ti10Mo6Zr4Sn3Nb (Ti-B12), a novel $\beta$-type titanium alloy designed to address these clinical shortcomings. Methods: Ti-B12 was synthesized and tested for mechanical properties, in vitro biocompatibility using MC3T3-E1 cells, and in vivo osseointegration in rabbit models. Results: Ti-B12 demonstrated a low elastic modulus (50–60.7 GPa) and high strength (~1,000 MPa). It showed no systemic toxicity or irritation and promoted superior osteoblast adhesion and ALP secretion compared to Ti6Al4V. In vivo tests confirmed direct bone fusion without fibrous encapsulation after three months. Conclusion: Ti-B12 is a promising, non-toxic alternative for clinical orthopedic applications due to its excellent mechanical matching and osseointegration.

Introduction

For decades, Ti6Al4V has served as the "gold standard" for orthopedic and dental implants. However, its clinical utility is limited by two primary factors. First, the modulus mismatch: Ti6Al4V is significantly stiffer (~110 GPa) than human cortical bone (17–20 GPa), leading to "stress shielding" where the implant bears the load, causing surrounding bone to resorb. Second, the toxicity of Aluminum (Al) and Vanadium (V) ions, which can leach into the body and cause long-term health issues.

To overcome these hurdles, researchers developed Ti10Mo6Zr4Sn3Nb (Ti-B12). This alloy utilizes non-toxic $\beta$-stabilizing elements (Mo, Zr, Sn, Nb) to create a material that more closely mimics the mechanical properties of bone while ensuring biological safety.

Materials and Methods

The Ti-B12 alloy was synthesized using consumable vacuum arc melting (VAR) to ensure chemical homogeneity. The resulting ingots underwent free forging and were processed into bars through a mill and straightener.

Figure 1: Synthesis process of Ti-B12 titanium alloy, from raw materials and electrode blocks to vacuum arc remelting (VAR) and final bar production.

The study employed a multi-stage validation pipeline:

  • Mechanical Characterization: Tensile strength and elastic modulus were measured to assess structural suitability.
  • In Vitro Evaluation: MC3T3-E1 mouse osteoblast-like cells were cultured on the alloy to monitor morphology, proliferation, and apoptosis. Osteogenic markers, including Alkaline Phosphatase (ALP) activity and gene expression (OCN, Runx2), were quantified.
  • In Vivo Safety and Function: Acute systemic toxicity was tested in mice, while skin and intradermal irritation were assessed in rabbits. Finally, Ti-B12 rods were implanted into rabbit femurs for three months to evaluate osseointegration via X-ray and histology.

Results and Discussion

Mechanical and Biological Superiority

Ti-B12 achieved a remarkably low elastic modulus of 50–60.7 GPa, roughly half that of Ti6Al4V, while maintaining a high tensile strength of ~1,000 MPa. This combination is critical for reducing stress shielding while ensuring the implant can withstand physiological loads.

Biologically, Ti-B12 proved superior in promoting cell adhesion. SEM analysis showed osteoblasts on Ti-B12 developed more extensive pseudopodia (arm-like projections) compared to those on Ti6Al4V. Furthermore, Ti-B12 induced significantly higher ALP secretion ($p < 0.05$), a key indicator of early-stage bone formation and mineralization.

Osseointegration and Safety

The safety profile of Ti-B12 was exemplary, with no recorded systemic toxicity or allergic reactions. The most significant finding was the quality of the bone-implant interface. In the rabbit model, Ti-B12 implants showed direct "fusion" with the surrounding bone. Unlike many traditional materials that become wrapped in a layer of fibrous connective tissue—which can lead to implant loosening—Ti-B12 demonstrated true osseointegration.

Conclusion

The novel $\beta$-titanium alloy Ti-B12 successfully combines high mechanical strength with a low elastic modulus and excellent biocompatibility. By eliminating toxic elements and enhancing the bone-bonding interface, Ti-B12 represents a significant advancement over Ti6Al4V and is a strong candidate for next-generation orthopedic implants. Future work will focus on long-term durability and the impact of advanced manufacturing techniques like 3D printing on the alloy's performance.

Summary updated

Abstract

<b>Introduction:</b> Ti6Al4V titanium alloy is widely used in producing orthopedic and maxillofacial implants, but drawbacks include high elastic modulus, poor osseointegration performance, and toxic elements. A new medical titanium alloy material with better comprehensive performance is urgently needed in the clinic. <b>Methods:</b> Ti10Mo6Zr4Sn3Nb titanium alloy (referred to as Ti-B12) is a unique medical <i>ß</i> titanium alloy material developed by us. The mechanical properties of Ti-B12 depict that it has advantages, such as high strength, low elastic modulus, and fatigue resistance. In our study, the biocompatibility and osseointegration properties of Ti-B12 titanium alloy are further studied to provide theoretical guidance for its clinical transformation. <b>Results and Discussion:</b> The titanium alloy Ti-B12 displays no significant effect on MC3T3-E1 cell morphology, proliferation, or apoptosis <i>in vitro</i>. Neither Ti-B12 titanium alloy nor Ti6Al4V titanium alloy depicts a significant difference (<i>p</i> > 0.05); Ti-B12 material extract injected into the abdominal cavity of mice does not cause acute systemic toxicity. The skin irritation test and intradermal irritation test reveal that Ti-B12 does not cause skin allergic reactions in rabbits. Compared to Ti6Al4V, Ti-B12 titanium alloy material has more advantages in promoting osteoblast adhesion and ALP secretion (<i>p</i> < 0.05). Although there is no significant difference in OCN and Runx2 gene expression between the three groups on the 7th and 14th days of differentiation induction (<i>p</i> > 0.05), the expression of Ti-B12 group is higher than that of Ti6Al4V group and blank control group. Furthermore, the rabbit <i>in vivo</i> test present that 3 months after the material is implanted in the lateral epicondyle of the rabbit femur, the Ti-B12 material fuses with the surrounding bone without connective tissue wrapping. This study confirms that the new β-titanium alloy Ti-B12 not only has low toxicity and does not cause rejection reaction but also has better osseointegration performance than the traditional titanium alloy Ti6Al4V. Therefore, Ti-B12 material is expected to be further promoted in clinical practice.
BibTeX
@inproceedings{liu2023biocompatibility,
  author = {Jiantao Liu and Kao Wang and Xingyuan Li and Xiwei Zhang and Xi Gong and Yihan Zhu and Zhiwei Ren and Bin Zhang and Jun Cheng},
  title = {{Biocompatibility and osseointegration properties of a novel high strength and low modulus β- Ti10Mo6Zr4Sn3Nb alloy}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2023},
  doi = {10.3389/fbioe.2023.1127929},
}
Figure